Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort
Revista Española de Quimioterapia · 10.01.2025 · 38 (1) · 40-47
DOI: 10.37201/req/080.2024 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Revista Española de Quimioterapia, online erschienen am 20.11.2024. Verfasst von D Cecchini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Diego Cecchini, Helios Salud SA, Perú 1511/15, Buenos Aires, C1141ACG, Argentina. dcecchini@heliossalud.com.ar. Hauptthemen laut MEDLINE: HIV Infections, Emtricitabine, Anti-HIV Agents, Tenofovir. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Real-world data on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) fixed-dose combination from resource-constrained settings like Latin America are limited. Material and methods. We conducted an observational retrospective cohort study of treatment-naive (TN, n=315) and treatment-experienced (TE, n= 2356) people living with HIV prescribed BIC/FTC/TAF in Argentina from 10/2019 to 12/2021, with 24 and 48-week follow-up data analyzed for virological suppression, persistence, safety, and metabolic parameters. Patient-reported outcomes were assessed via across-sectional online survey.
Results
Baseline characteristics: median age 45 years, 72.2% male, 99.6% Hispanic/Latino ethnicity. Treatment per sistence at 48 weeks was 99.3% (TN) and 99.5% (TE). Virological suppression rates (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diego Cecchini, Helios Salud SA, Perú 1511/15, Buenos Aires, C1141ACG, Argentina. dcecchini@heliossalud.com.ar.
Zitieren
APA
Cecchini, D., Brizuela, M., Seleme, M. S., Mingrone, M. V., Copertari, G., Bacelar, B., Mauas, R., Bottaro, E., & Cassetti, I. (2025). Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort. Revista Española de Quimioterapia, 38(1), 40-47. https://doi.org/10.37201/req/080.2024
Vancouver
Cecchini D, Brizuela M, Seleme MS, Mingrone MV, Copertari G, Bacelar B, et al. Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort. Revista Española de Quimioterapia. 2025;38(1):40-47. doi:10.37201/req/080.2024
BibTeX
@article{Cecchini2025,
author = {Cecchini, D and Brizuela, M and Seleme, M S and Mingrone, M V and Copertari, G and Bacelar, B and Mauas, R and Bottaro, E and Cassetti, I},
title = {Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort},
journal = {Revista Española de Quimioterapia},
year = {2025},
volume = {38},
number = {1},
pages = {40--47},
doi = {10.37201/req/080.2024}
}
EUVIMED